首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Properties of Streptomyces fradiae Mutants Blocked in Biosynthesis of the Macrolide Antibiotic Tylosin
【2h】

Properties of Streptomyces fradiae Mutants Blocked in Biosynthesis of the Macrolide Antibiotic Tylosin

机译:大环内酯类抗生素泰乐菌素生物合成中受阻的链霉菌突变体的特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We isolated numerous mutants of Streptomyces fradiae blocked in tylosin biosynthesis after N-methyl-N′-nitro-N-nitrosoguanidine mutagenesis. These mutants were classified into nine groups, based upon the tylosin-like compounds produced and upon cofermentation analyses. More than 80% of the mutants isolated produced no tylosin-like compounds, and the majority of these were blocked only in the formation of tylactone. Four classes of mutants blocked in the biosynthesis or addition of tylosin sugars were isolated; tylA mutants were blocked in the formation of all three tylosin sugars, whereas tylB, tylC, and tylD mutants were blocked specifically in the biosynthesis or the addition of mycaminose, mycarose, and 6-deoxy-d-allose, respectively. Two classes of mutants (tylH and tylI) blocked in specific oxidations of tylactone and two classes (tylE and tylF) blocked in specific O-methylations of demethylmacrocin and macrocin were also characterized. Cofermentation and bioconversion studies with these mutants suggested the following relationships: (i) the tylosin sugars are derived from a common intermediate; (ii) tylactone is the first intermediate which can be excreted in appreciable quantities; (iii) the addition of mycaminose to the C-5 hydroxyl group of tylactone must precede oxidations at C-20 and C-23; (iv) oxidation at C-20 normally precedes the attachment of mycarose to the 4′ hydroxyl position of mycaminose; and (v) 6-deoxy-d-allose is added to the C-23 hydroxyl position of the lactone and subsequently O-methylated at 2‴ and 3‴ positions. The O-methylations appear to be the final two steps in tylosin biosynthesis, and the 2‴ O-methylation must occur before the 3‴ O-methylation can take place. All of the tyl mutants except the tylG mutants produced relatively high levels of tylosin-like intermediates or shunt products. Mutants blocked in specific steps other than 3‴ O-methylation, including a mutant blocked in 2‴ O-methylation of demethylmacrocin, produced normal levels of macrocin O-methyltransferase. Mutants apparently containing specific tylosin structural gene mutations produced normal levels of aerial mycelia and spores, produced low levels of tylosin aldehyde reductase, and were resistant to high levels of tylosin. However, three atypical tylG mutants produced no tylosin-like compounds, could not cosynthesize tylosin with any other tyl mutant, could not bioconvert tylactone or macrocin to tylosin, and produced no macrocin O-methyltransferase. These three mutants produced elevated levels of tylosin aldehyde reductase. In addition, one was very succeptible to tylosin and did not produce aerial mycelia or spores.
机译:在N-甲基-N'-硝基-N-亚硝基胍诱变后,我们分离了在泰乐菌素生物合成中受阻的大量链霉菌突变体。根据产生的泰乐菌素样化合物和经发酵分析,将这些突变体分为九类。分离出的突变体中有80%以上没有产生类似泰乐菌素的化合物,其中大多数仅在酪内酯的形成中被阻断。分离了四类在生物合成或添加泰乐菌糖中受阻的突变体。 tylA突变体在所有三种泰乐菌素糖的形成中均被阻滞,而tylB,tylC和tylD突变体分别在生物合成或添加Mycaminose,Mycarose和6-deoxy-d-Allose时被特异性阻滞。还对两类突变体(tylH和tylI)在丁内酯的特异性氧化中被阻滞,以及两类突变体(tylE和tylF)在脱甲基大黄素和大霉素的特定O-甲基化中被阻滞进行了表征。与这些突变体的发酵和生物转化研究表明以下关系:(i)泰乐菌糖源于一种常见的中间体; (ii)丁内酯是第一个可以大量排出的中间体; (iii)必须在酪氨酸的C-5和C-23的氧化反应之前向其内酯的C-5羟基添加麦芽糖酶; (iv)C-20的氧化反应通常在将Mycarose连接到Mycaminose的4'羟基位置之前; (v)将6-脱氧-d-阿洛糖加到内酯的C-23羟基位置,然后在2′和3′位进行O-甲基化。 O-甲基化似乎是泰乐菌素生物合成的最后两个步骤,必须先发生2′O-甲基化,然后才能进行3′O-甲基化。除tylG突变体外,所有tyl突变体均产生相对较高水平的泰乐菌素样中间体或旁路产物。除3′O-甲基化以外的特定步骤受阻的突变体,包括在脱甲基大分子霉素的2′O-甲基化中受阻的突变体,产生了正常水平的巨霉素O-甲基转移酶。显然含有特定泰乐菌素结构基因突变的突变体产生正常水平的气生菌丝体和孢子,产生较低水平的泰乐菌素醛还原酶,并且对高水平的泰乐菌素具有抗性。然而,三个非典型的tylG突变体没有产生类似泰乐菌素的化合物,不能与任何其他tyl突变体共合成泰乐菌素,不能将酪氨酸或大环素生物转化为泰乐菌素,也没有产生大环素 O -甲基转移酶。这三个突变体产生的泰乐菌素醛还原酶水平升高。另外,一种对泰乐菌素非常敏感,并且不产生气生菌丝体或孢子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号